Untitled

Abstract

The main purpose of this current work is to optimize the formulation and in-vitro evaluation of gabapentin niosomes. Methods: Niosomes are formulated by utilizing the thin film method. Gabapentin niosomes are prepared with cholesterol and span 80. Pre-formulation and post-formulation studies were carried out for optimized gabapentin niosomes. Such as FTIR, DSC, Zeta, Particle size, TEM, SEM, and in-vitro drug release studies. Report: Gabapentin medication preformulation experiments were carried out. The ultraviolet spectroscopic maximum of gabapentin was found to be 206nm. Within the concentration range of 2-10 g/ml of drug in phosphate buffer 7.4 solutions; gabapentin follows Beers law with a slope of 0.1086 x and an R 2 value of 0.9985. The particle size was determined to be round and spherical in the improved formulation F7. The particle sizes are in the 50-120mm range. Particle's external morphology/outer surface morphology were determined. Conclusion: The goal of this study was to optimize the formulation and in-vitro evaluation of gabapentin niosomes for epilepsy treatment. As a result, the current research focuses on increasing drug permeability and encapsulating the drug in niosomes vesicles for long-term central nervous system drug delivery.